The role of the microbiome in drug resistance in gastrointestinal cancers

References

• Hekmatshoar Y, Saadat YR, Khatibi SMH, et al. The impact of tumor and gut microbiotas on cancer therapy: beneficial or detrimental? Life Sci. 2019;233:116680.
   PubMed Web of Science ®Google Scholar
• Rajagopala SV, Vashee S, Oldfield LM, et al. The human microbiome and cancer. Cancer Prev Res (Phila). 2017;10(4):226–234.
   PubMed Web of Science ®Google Scholar
• Vande Voorde J, Sabuncuoglu S, Noppen S, et al. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine. J Biol Chem. 2014;289(19):13054–13065.
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–141.
   PubMed Web of Science ®Google Scholar
• Inamura K. Roles of microbiota in response to cancer immunotherapy. Semin Cancer Biol. 2020;65:164–175.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Khan MAW, Hermann A, et al. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377–388.
   PubMed Web of Science ®Google Scholar
• Collins D, Hogan AM, Winter DC. Microbial and viral pathogens in colorectal cancer. Lancet Oncol. 2011;12(5):504–512.
   PubMed Web of Science ®Google Scholar
• Ma W, Mao Q, Xia W, et al. Gut microbiota shapes the efficiency of cancer therapy. Front Microbiol. 2019;10:1050.
   PubMed Web of Science ®Google Scholar
• Zaidi AH, Kelly LA, Kreft RE, et al. Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma. BMC Cancer. 2016;16:52.
   PubMed Web of Science ®Google Scholar
• Blackett KL, Siddhi SS, Cleary S, et al. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett’s and oesophageal carcinoma: association or causality? Aliment Pharmacol Ther. 2013;37(11):1084–1092.
   PubMed Web of Science ®Google Scholar
• May M, Abrams JA. Emerging insights into the esophageal microbiome. Curr Treat Options Gastroenterol. 2018;16(1):72–85.
   PubMedGoogle Scholar
• Gagliardi D, Makihara S, Corsi PR, et al. Microbial flora of the normal esophagus. Dis Esophagus. 1998;11(4):248–250.
   PubMedGoogle Scholar
• Finlay IG, Wright PA, Menzies T, et al. Microbial flora in carcinoma of oesophagus. Thorax. 1982;37(3):181–184.
   PubMed Web of Science ®Google Scholar
• Lau WF, Wong J, Lam KH, et al. Oesophageal microbial flora in carcinoma of the oesophagus. Aust NZ J Surg. 1981;51(1):52–55.
   PubMedGoogle Scholar
• Yang L, Lu X, Nossa CW, et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137(2):588–597.
   PubMed Web of Science ®Google Scholar
• Arthur JC, Gharaibeh RZ, Muhlbauer M, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun. 2014;5:4724.
   PubMed Web of Science ®Google Scholar
• Yamamura K, Baba Y, Nakagawa S, et al. Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res. 2016;22(22):5574–5581.
   PubMed Web of Science ®Google Scholar
• Elliott DRF, Walker AW, O’Donovan M, et al. A non-endoscopic device to sample the oesophageal microbiota: a case-control study. Lancet Gastroenterol Hepatol. 2017;2(1):32–42.
   PubMed Web of Science ®Google Scholar
• Lu Q, Ding H, Li W. Role of Toll-like receptors in microbiota-associated gastrointestinal cancer metastasis. J Cancer Res Ther. 2013;9(Suppl):S142–149.
   PubMedGoogle Scholar
• Willey JM, Sherwood L, Woolverton CJ. Prescott’s microbiology. McGraw-Hill; 2011.
   Google Scholar
• Brawner KM, Morrow CD, Smith PD. Gastric microbiome and gastric cancer. Cancer J. 2014;20(3):211–216.
   PubMed Web of Science ®Google Scholar
• Cover TL, Krishna US, Israel DA, et al. Induction of gastric epithelial cell apoptosis by Helicobacter pylori vacuolating cytotoxin. Cancer Res. 2003;63(5):951–957.
   PubMed Web of Science ®Google Scholar
• Gebert B, Fischer W, Weiss E, et al. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science. 2003;301(5636):1099–1102.
   PubMed Web of Science ®Google Scholar
• Wroblewski LE, Peek RM Jr., Coburn LA. The role of the microbiome in gastrointestinal cancer. Gastroenterol Clin North Am. 2016;45(3):543–556.
   PubMed Web of Science ®Google Scholar
• Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A. 2008;105(3):1003–1008.
   PubMed Web of Science ®Google Scholar
• Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. Isme J. 2011;5(4):574–579.
   PubMed Web of Science ®Google Scholar
• Lofgren JL, Whary MT, Ge Z, et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology. 2011;140(1):210–220.
   PubMed Web of Science ®Google Scholar
• Lertpiriyapong K, Whary MT, Muthupalani S, et al. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis. Gut. 2014;63(1):54–63.
   PubMed Web of Science ®Google Scholar
• Shao D, Vogtmann E, Liu A, et al. Microbial characterization of esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-risk region of China. Cancer. 2019;125(22):3993–4002.
   PubMed Web of Science ®Google Scholar
• Dicksved J, Lindberg M, Rosenquist M, et al. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol. 2009;58(Pt 4):509–516.
   PubMed Web of Science ®Google Scholar
• Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65(2):330–339.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.
   PubMed Web of Science ®Google Scholar
• Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–215.
   PubMed Web of Science ®Google Scholar
• Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019;16(11):690–704.
   PubMed Web of Science ®Google Scholar
• Wong SH, Zhao L, Zhang X, et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology. 2017;153(6):1621–1633 e1626.
   PubMed Web of Science ®Google Scholar
• Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22(2):299–306.
   PubMed Web of Science ®Google Scholar
• Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66(1):70–78.
   PubMed Web of Science ®Google Scholar
• Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One. 2011;6(1):e16393.
   PubMed Web of Science ®Google Scholar
• Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33:1381–1390.
   PubMed Web of Science ®Google Scholar
• Gagniere J, Raisch J, Veziant J, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016;22(2):501–518.
   PubMed Web of Science ®Google Scholar
• Balsano R, Tommasi C, Garajova I. State of the art for metastatic pancreatic cancer treatment: where are we now? Anticancer Res. 2019;39(7):3405–3412.
   PubMed Web of Science ®Google Scholar
• Caparello C, Meijer LL, Garajova I, et al. FOLFIRINOX and translational studies: towards personalized therapy in pancreatic cancer. World J Gastroenterol. 2016;22(31):6987–7005.
   PubMed Web of Science ®Google Scholar
• Frega G, Garajova I, Palloni A, et al. Brain metastases from biliary tract cancer: a monocentric retrospective analysis of 450 patients. Oncology. 2018;94(1):7–11.
   PubMed Web of Science ®Google Scholar
• Tovoli F, Lorenzo S, Barbera MA, et al. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. Future Oncol. 2017;13(21):1893–1905.
   PubMed Web of Science ®Google Scholar
• Mima K, Nakagawa S, Sawayama H, et al. The microbiome and hepatobiliary-pancreatic cancers. Cancer Lett. 2017;402:9–15.
   PubMed Web of Science ®Google Scholar
• Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58(1):120–127.
   PubMed Web of Science ®Google Scholar
• Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59–64.
   PubMed Web of Science ®Google Scholar
• Fox JG, Feng Y, Theve EJ, et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut. 2010;59(1):88–97.
   PubMed Web of Science ®Google Scholar
• Nicoletti A, Ponziani FR, Nardella E, et al. Biliary tract microbiota: a new kid on the block of liver diseases? Eur Rev Med Pharmacol Sci. 2020;24(5):2750–2775.
   PubMed Web of Science ®Google Scholar
• Shimoyama T, Takahashi R, Abe D, et al. Serological analysis of Helicobacter hepaticus infection in patients with biliary and pancreatic diseases. J Gastroenterol Hepatol. 2010;25(Suppl 1):S86–89.
   PubMedGoogle Scholar
• Koshiol J, Wozniak A, Cook P, et al. Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis. Cancer Med. 2016;5(11):3310–3335.
   PubMed Web of Science ®Google Scholar
• Michaud DS, Joshipura K, Giovannucci E, et al. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J Natl Cancer Inst. 2007;99(2):171–175.
   PubMedGoogle Scholar
• Fan X, Alekseyenko AV, Wu J, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018;67(1):120–127.
   PubMed Web of Science ®Google Scholar
• Michaud DS, Izard J, Wilhelm-Benartzi CS, et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut. 2013;62(12):1764–1770.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi K, Nosho K, Sukawa Y, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget. 2015;6(9):7209–7220.
   PubMedGoogle Scholar
• Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971–976.
   PubMed Web of Science ®Google Scholar
• Goubet AG, Daillere R, Routy B, et al. The impact of the intestinal microbiota in therapeutic responses against cancer. C R Biol. 2018;341(5):284–289.
   PubMed Web of Science ®Google Scholar
• Al Nabhani Z, Dietrich G, Hugot JP, et al. Nod2: the intestinal gate keeper. PLoS Pathog. 2017;13(3):e1006177.
   PubMed Web of Science ®Google Scholar
• Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011;18(1):18–25.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–970.
   PubMed Web of Science ®Google Scholar
• Miko E, Kovacs T, Sebo E, et al. Microbiome-microbial metabolome-cancer cell interactions in breast cancer-familiar, but unexplored. Cells. 2019; 8(4). DOI:10.3390/cells8040293
   PubMedGoogle Scholar
• Westman EL, Canova MJ, Radhi IJ, et al. Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012;19(10):1255–1264.
   PubMed Web of Science ®Google Scholar
• Yan A, Culp E, Perry J, et al. Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018;4(1):68–76.
   PubMed Web of Science ®Google Scholar
• Panebianco C, Potenza A, Andriulli A, et al. Exploring the microbiota to better understand gastrointestinal cancers physiology. Clin Chem Lab Med. 2018;56(9):1400–1412.
   PubMed Web of Science ®Google Scholar
• Rea D, Coppola G, Palma G, et al. Microbiota effects on cancer: from risks to therapies. Oncotarget. 2018;9(25):17915–17927.
   PubMedGoogle Scholar
• Wilkinson EM, Ilhan ZE, Herbst-Kralovetz MM. Microbiota-drug interactions: impact on metabolism and efficacy of therapeutics. Maturitas. 2018;112:53–63.
   PubMed Web of Science ®Google Scholar
• Ding C, Tang W, Fan X, et al. Intestinal microbiota: a novel perspective in colorectal cancer biotherapeutics. Onco Targets Ther. 2018;11:4797–4810.
   PubMed Web of Science ®Google Scholar
• Lin XB, Dieleman LA, Ketabi A, et al. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLoS One. 2012;7(7):e39764.
   PubMed Web of Science ®Google Scholar
• Dashnyam P, Mudududdla R, Hsieh TJ, et al. beta-Glucuronidases of opportunistic bacteria are the major contributors to xenobiotic-induced toxicity in the gut. Sci Rep. 2018;8(1):16372.
   PubMedGoogle Scholar
• Pollet RM, D’Agostino EH, Walton WG, et al. An atlas of beta-glucuronidases in the human intestinal microbiome. Structure. 2017;25(7):967–977 e965.
   PubMed Web of Science ®Google Scholar
• Peters GJ. Novel developments in the use of antimetabolites. Nucleosides Nucleotides Nucleic Acids. 2014;33(4–6):358–374.
   PubMed Web of Science ®Google Scholar
• Deng X, Li Z, Li G, et al. Comparison of microbiota in patients treated by surgery or chemotherapy by 16S rRNA sequencing reveals potential biomarkers for colorectal cancer therapy. Front Microbiol. 2018;9:1607.
   PubMed Web of Science ®Google Scholar
• Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–355.
   PubMed Web of Science ®Google Scholar
• Wu J, Li Q, Fu X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity. Transl Oncol. 2019;12(6):846–851.
   PubMed Web of Science ®Google Scholar
• Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;816460:2015.
   Google Scholar
• Bronckaers A, Balzarini J, Liekens S. The cytostatic activity of pyrimidine nucleosides is strongly modulated by mycoplasma hyorhinis infection: implications for cancer therapy. Biochem Pharmacol. 2008;76(2):188–197.
   PubMed Web of Science ®Google Scholar
• Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548–563 e516.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Serdjebi C, Peters GJ, et al. Pharmacokinetics and pharmacogenetics of gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016;78(1):1–12.
   PubMed Web of Science ®Google Scholar
• Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357(6356):1156–1160.
   PubMed Web of Science ®Google Scholar
• Choy ATF, Carnevale I, Coppola S, et al. The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine. Expert Rev Mol Diagn. 2018;18(12):1005–1009.
   PubMed Web of Science ®Google Scholar
• Lehouritis P, Cummins J, Stanton M, et al. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015;5:14554.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Ma Y, Raoult D, et al. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366–1370.
   PubMed Web of Science ®Google Scholar
• Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235–247.
   PubMed Web of Science ®Google Scholar
• Costea PI, Zeller G, Sunagawa S, et al. Towards standards for human fecal sample processing in metagenomic studies. Nat Biotechnol. 2017;35(11):1069–1076.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
   PubMed Web of Science ®Google Scholar
• Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–1084.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103.
   PubMed Web of Science ®Google Scholar
• Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283–2289.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–1089.
   PubMed Web of Science ®Google Scholar
• Baskar R, Dai J, Wenlong N, et al. Biological response of cancer cells to radiation treatment. Front Mol Biosci. 2014;1:24.
   PubMed Web of Science ®Google Scholar
• Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271–285.
   PubMed Web of Science ®Google Scholar
• Barker HE, Paget JT, Khan AA, et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409–425.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72.
   PubMed Web of Science ®Google Scholar
• Olivas AD, Shogan BD, Valuckaite V, et al. Intestinal tissues induce an SNP mutation in Pseudomonas aeruginosa that enhances its virulence: possible role in anastomotic leak. PLoS One. 2012;7(8):e44326.
   PubMed Web of Science ®Google Scholar
• Ferreira MR, Andreyev HJN, Mohammed K, et al. Microbiota- and radiotherapy-induced gastrointestinal side-effects (MARS) study: a large pilot study of the microbiome in acute and late-radiation enteropathy. Clin Cancer Res. 2019;25(21):6487–6500.
   PubMed Web of Science ®Google Scholar
• Alves A, Panis Y, Trancart D, et al. Factors associated with clinically significant anastomotic leakage after large bowel resection: multivariate analysis of 707 patients. World J Surg. 2002;26(4):499–502.
   PubMed Web of Science ®Google Scholar
• Frasson M, Granero-Castro P, Ramos Rodriguez JL, et al. Risk factors for anastomotic leak and postoperative morbidity and mortality after elective right colectomy for cancer: results from a prospective, multicentric study of 1102 patients. Int J Colorectal Dis. 2016;31(1):105–114.
   PubMed Web of Science ®Google Scholar
• Russ AJ, Casillas MA. Gut microbiota and colorectal surgery: impact on postoperative complications. Clin Colon Rectal Surg. 2016;29(3):253–257.
   PubMed Web of Science ®Google Scholar
• Cohn I Jr., Rives JD. Antibiotic protection of colon anastomoses. Ann Surg. 1955;141(5):707–717.
   PubMed Web of Science ®Google Scholar
• Shogan BD, Belogortseva N, Luong PM, et al. Collagen degradation and MMP9 activation by Enterococcus faecalis contribute to intestinal anastomotic leak. Sci Transl Med. 2015;7(286):286ra268.
   Web of Science ®Google Scholar
• Bloemen JG, Schreinemacher MH, de Bruine AP, et al. Butyrate enemas improve intestinal anastomotic strength in a rat model. Dis Colon Rectum. 2010;53(7):1069–1075.
   PubMed Web of Science ®Google Scholar
• Mathew AJ, Wann VC, Abraham DT, et al. The effect of butyrate on the healing of colonic anastomoses in rats. J Invest Surg. 2010;23(2):101–104.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Kinouchi T, Kataoka K, et al. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics. 1997;7(1):35–43.
   PubMedGoogle Scholar
• Schieber AM, Lee YM, Chang MW, et al. Disease tolerance mediated by microbiome E. coli involves inflammasome and IGF-1 signaling. Science. 2015;350(6260):558–563.
   PubMed Web of Science ®Google Scholar
• Pouncey AL, Scott AJ, Alexander JL, et al. Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment. Ecancermedicalscience. 2018 Sept 5;12:868.
   PubMed Web of Science ®Google Scholar
• Kong R, Liu T, Zhu X, et al. Old drug new use - Amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. Clin Cancer Res. 2014 July 1;20(13):3521–3530.
   PubMed Web of Science ®Google Scholar
• Wieczorska K, Stolarek M, Stec R. The role of the gut microbiome in colorectal cancer: where are we? Where are we going? Clin Colorectal Cancer. 2020;19(1):5–13.
   PubMed Web of Science ®Google Scholar
• Halley A, Leonetti A, Gregori A, et al. The role of the microbiome in cancer and therapy efficacy: focus on lung cancer. Anticancer Res. 2020;40:4807–4818.
   PubMed Web of Science ®Google Scholar
• Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220–230.
   PubMed Web of Science ®Google Scholar
• Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994–1002.
   PubMed Web of Science ®Google Scholar
• Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437–1444.
   PubMed Web of Science ®Google Scholar
• Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8(4):403–416.
   PubMed Web of Science ®Google Scholar
• Kubiak AM. Nigel PM The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy. Res Microbiol. 2015;166(4):244–254.
   PubMed Web of Science ®Google Scholar
• Heap JT, Theys J, Ehsaan M, et al. Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. Oncotarget. 2014;5(7):1761.
   PubMedGoogle Scholar
• Ke W, Saba JA, Yao CH, et al. Dietary serine-microbiota interaction enhances chemotherapeutic toxicity without altering drug conversion. Nat Commun. 2020;11(1):2587.
   PubMed Web of Science ®Google Scholar
• Anfossi S, Calin GA. Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy. Cancer Drug Resist. 2020;2020:3.
   Google Scholar
• Tsatsaronis JA, Franch-Arroyo S, Resch U, et al. Extracellular vesicle RNA: a universal mediator of microbial communication? Trends Microbiol. 2018 May;26(5):401–410.
   PubMed Web of Science ®Google Scholar